Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

NCT06522386 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT06522386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06522386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 30, 2025
Completion date
February 28, 2029
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma